The collaboration aims to improve diagnosis and management of disease in critical care settings within hospitals, such as emergency departments, coronary units and ICUs.
The new alliance unites Philips’ existing strengths in medical technology, patient monitoring and healthcare IT (including solutions aimed at helping clinicians to make more informed decisions) with bioMerieux’s expertise in the development of biological assays and knowledge of cardiovascular and infectious disease markers, said the companies.
As per the agreement, bioMerieux will have access to Philips’ proprietary Magnotech technology for hospital-based testing applications. Commercial solutions resulting from the partnership will be co-branded by Philips and bioMerieux, with bioMerieux being the distributor worldwide. The two companies intend to have the products in the market by 2013.
The new devices will be immunoassay-based and employ Philips’ new Magnotech biosensor platform. They are intended to assist clinicians in time-critical decision-making by reducing delays involved in laboratory-based testing.
